Actinium Pharmaceuticals ... (ATNM)
Actinium Pharmaceuticals Statistics
Share Statistics
Actinium Pharmaceuticals has 31.2M shares outstanding. The number of shares has increased by 4.74% in one year.
| Shares Outstanding | 31.2M |
| Shares Change (YoY) | 4.74% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 26.18% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 4,258 |
| FTD / Avg. Volume | 0.67% |
Short Selling Information
The latest short interest is 1.67M, so 5.36% of the outstanding shares have been sold short.
| Short Interest | 1.67M |
| Short % of Shares Out | 5.36% |
| Short % of Float | 5.36% |
| Short Ratio (days to cover) | 4.15 |
Valuation Ratios
The PE ratio is -0.99 and the forward PE ratio is -1.5. Actinium Pharmaceuticals's PEG ratio is 0.03.
| PE Ratio | -0.99 |
| Forward PE | -1.5 |
| PS Ratio | 0 |
| Forward PS | 0.4 |
| PB Ratio | 1.16 |
| P/FCF Ratio | -1.15 |
| PEG Ratio | 0.03 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Actinium Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.14, with a Debt / Equity ratio of 0.05.
| Current Ratio | 9.14 |
| Quick Ratio | 9.14 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | -0.04 |
| Debt / FCF | -0.05 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,033,594.59 |
| Employee Count | 37 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -82.86% in the last 52 weeks. The beta is -0.27, so Actinium Pharmaceuticals's price volatility has been lower than the market average.
| Beta | -0.27 |
| 52-Week Price Change | -82.86% |
| 50-Day Moving Average | 1.31 |
| 200-Day Moving Average | 1.93 |
| Relative Strength Index (RSI) | 57.96 |
| Average Volume (20 Days) | 639,980 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -42.12M |
| Net Income | -38.24M |
| EBITDA | -37.43M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.27 |
Balance Sheet
The company has 72.9M in cash and 1.57M in debt, giving a net cash position of 71.33M.
| Cash & Cash Equivalents | 72.9M |
| Total Debt | 1.57M |
| Net Cash | 71.33M |
| Retained Earnings | -375.83M |
| Total Assets | 76.9M |
| Working Capital | 66.36M |
Cash Flow
In the last 12 months, operating cash flow was -33.07M and capital expenditures -11K, giving a free cash flow of -33.08M.
| Operating Cash Flow | -33.07M |
| Capital Expenditures | -11K |
| Free Cash Flow | -33.08M |
| FCF Per Share | -1.1 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ATNM does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for ATNM is $5, which is 233.3% higher than the current price. The consensus rating is "Buy".
| Price Target | $5 |
| Price Target Difference | 233.3% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Stock Splits
The last stock split was on Aug 11, 2020. It was a backward split with a ratio of 1:30.
| Last Split Date | Aug 11, 2020 |
| Split Type | backward |
| Split Ratio | 1:30 |
Scores
| Altman Z-Score | -7.06 |
| Piotroski F-Score | 1 |